{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:41:43Z","timestamp":1791837703886,"version":"4.3.4"},"reference-count":276,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007247","name":"Svenska Kulturfonden","doi-asserted-by":"publisher","award":["190913"],"award-info":[{"award-number":["190913"]}],"id":[{"id":"10.13039\/501100007247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007247","name":"Svenska Kulturfonden","doi-asserted-by":"publisher","award":["188147"],"award-info":[{"award-number":["188147"]}],"id":[{"id":"10.13039\/501100007247","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u00c5bo Akademi University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rapid occurrence of bacterial antibiotic resistance poses a significant threat to public health\u00a0worldwide. Since particularly multidrug-resistant (MDR) pathogens are becoming untreatable with currently available\u00a0antibiotics, new treatment modalities must be deployed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review explores the recent advancements and the enduring challenges in new antibacterial\u00a0development for drug-resistant organisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We describe how bacterial resistance to antibiotics arises and discuss why the traditional drug discovery\u00a0routes are inefficient. The best alternative strategies to overcome these challenges might include exploring new\u00a0bacterial pathways, utilizing compounds with antibacterial activities from the human microbiome, and repurposing\u00a0existing drugs. Moreover, novel drug delivery mechanisms that leverage, for example, nanotechnology-based\u00a0carriers may be breakthrough ideas that can increase antibiotic efficacy and, at the same time, reduce toxicity.\u00a0Current clinical trials of next-generation drugs indicate that some treatments possess excellent potential to\u00a0overcome the MDR issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the substantial obstacles to getting bench findings to the patient, numerous scientists are still\u00a0working towards this goal. Both the application of antibiotic stewardship principles and timely considerations through\u00a0the regulatory pathways are needed to release the next generation of antibiotics that are suitable for the fight\u00a0against superbugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-025-03871-x","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:35:43Z","timestamp":1750095343000},"page":"859-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Next Frontier: Unveiling Novel Approaches for Combating Multidrug-Resistant Bacteria"],"prefix":"10.1007","volume":"42","author":[{"given":"Praveen","family":"Mallari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila D.","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Alanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadak","family":"Howaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixin","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep K.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Rosenholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-126X","authenticated-orcid":false,"given":"Outi M. H.","family":"Salo-Ahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"3871_CR1","unstructured":"World Health Organization. Antimicrobial resistance. 2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance.\u00a0Accessed 09.06.2025"},{"issue":"4","key":"3871_CR2","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis. Pharm Ther. 2015;40(4):277\u201383.","journal-title":"Pharm Ther"},{"key":"3871_CR3","unstructured":"World Health Organization. Global action plan on antimicrobial resistance. 2015. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241509763. Accessed 09.06.2025"},{"key":"3871_CR4","unstructured":"World Health Organization. Critically important antimicrobials for human medicine: 5th revision. 2017. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241512220. Accessed 09.06.2025"},{"key":"3871_CR5","doi-asserted-by":"publisher","first-page":"f1493","DOI":"10.1136\/bmj.f1493","volume":"346","author":"R Smith","year":"2013","unstructured":"Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.","journal-title":"BMJ"},{"key":"3871_CR6","unstructured":"Centers for Disease Control and Prevention. 2019 antibiotic resistance threats report. 2019. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html. Accessed 09.06.2025"},{"key":"3871_CR7","unstructured":"European Centre for Disease Prevention and Control. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU\/EEA, 2016\u20132020. 2022. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Health-burden-infections-antibiotic-resistant-bacteria.pdf. Accessed 14 Apr 2025"},{"key":"3871_CR8","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net) \u2013 Annual epidemiological report 2023. 2024. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2023. Accessed 14 Apr 2025"},{"issue":"10325","key":"3871_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"11","key":"3871_CR10","doi-asserted-by":"publisher","first-page":"e1002184","DOI":"10.1371\/journal.pmed.1002184","volume":"13","author":"MEA de Kraker","year":"2016","unstructured":"de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11):e1002184.","journal-title":"PLoS Med"},{"key":"3871_CR11","unstructured":"World Bank. Drug-Resistant Infections: A Threat to Our Economic Future [Internet]. Washington, DC: World Bank; 2017. Available from: https:\/\/www.worldbank.org\/en\/topic\/health\/publication\/drug-resistant-infections-a-threat-to-our-economic-future. Accessed 09.11.2024"},{"issue":"1","key":"3871_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrmicro3380","volume":"13","author":"JMA Blair","year":"2015","unstructured":"Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42\u201351.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"3871_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance\u2013the need for global solutions. Lancet Infect Dis. 2013;13(12):1057\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"5759","key":"3871_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1126\/science.1120800","volume":"311","author":"VM D\u2019Costa","year":"2006","unstructured":"D\u2019Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science. 2006;311(5759):374\u20137.","journal-title":"Science"},{"issue":"7365","key":"3871_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10388","volume":"477","author":"VM D\u2019Costa","year":"2011","unstructured":"D\u2019Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457\u201361.","journal-title":"Nature"},{"issue":"2","key":"3871_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1574-6968.2009.01635.x","volume":"296","author":"M Petrova","year":"2009","unstructured":"Petrova M, Gorlenko Z, Mindlin S. Molecular structure and translocation of a multiple antibiotic resistance region of a Psychrobacter psychrophilus permafrost strain. FEMS Microbiol Lett. 2009;296(2):190\u20137. https:\/\/doi.org\/10.1111\/j.1574-6968.2009.01635.x.","journal-title":"FEMS Microbiol Lett."},{"issue":"2","key":"3871_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbrc.2014.05.090","volume":"453","author":"J Sun","year":"2014","unstructured":"Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun. 2014;453(2):254\u201367.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3871_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"3871_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijid.2016.08.002","volume":"50","author":"S Gandra","year":"2016","unstructured":"Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008\u20132014. Int J Infect Dis. 2016;50:75\u201382.","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"3871_CR20","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","volume":"215","author":"LK Logan","year":"2017","unstructured":"Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28-36.","journal-title":"J Infect Dis"},{"issue":"14","key":"3871_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.2015.12480","volume":"314","author":"AY Guh","year":"2015","unstructured":"Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013. JAMA. 2015;314(14):1479\u201387.","journal-title":"JAMA"},{"issue":"1","key":"3871_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1473-3099(18)30648-0","volume":"19","author":"E Tacconelli","year":"2019","unstructured":"Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis. 2019;19(1):4\u20136.","journal-title":"Lancet Infect Dis"},{"key":"3871_CR23","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Long-Term Health and Economic Effects of Antimicrobial Resistance in the United States; Palmer GH, Buckley GJ, editors. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington (DC): National Academies Press (US); 2021 Oct 20. Summary. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK577280\/. Accessed 09.06.2025"},{"issue":"4","key":"3871_CR24","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277\u201383.","journal-title":"P T"},{"issue":"1","key":"3871_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/CMR.00030-10","volume":"24","author":"LL Silver","year":"2011","unstructured":"Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71\u2013109.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"3871_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1377\/hlthaff.2014.1003","volume":"34","author":"K Outterson","year":"2015","unstructured":"Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff. 2015;34(2):277\u201385.","journal-title":"Health Aff"},{"key":"3871_CR27","unstructured":"Clift Charles, Gopinathan Unni, Morel Chantal M, Outterson Kevin, R\u00f8ttingen John-Arne, So Anthony, editors. Towards a new global business model for antibiotics: delinking revenues from sales. Centre on Global Health Security, Antimicrobial Resistance: Chatham House, London, UK; 2015."},{"issue":"11","key":"3871_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3390\/nano12111855","volume":"12","author":"TX Zong","year":"2022","unstructured":"Zong TX, Silveira AP, Morais JAV, Sampaio MC, Muehlmann LA, Zhang J, Jiang CS, Liu SK. Recent Advances in Antimicrobial Nano-Drug Delivery Systems. Nanomaterials (Basel). 2022;12(11):1855. https:\/\/doi.org\/10.3390\/nano12111855.","journal-title":"Nanomaterials (Basel)."},{"key":"3871_CR29","unstructured":"CDC. Core elements of hospital antibiotic stewardship programs. Antibiotic Prescribing and Use. Available from: https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/core-elements\/hospital.html. Accessed 09.06.2025"},{"issue":"15","key":"3871_CR30","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","volume":"115","author":"EY Klein","year":"2018","unstructured":"Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10014","key":"3871_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","volume":"387","author":"AH Holmes","year":"2016","unstructured":"Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176\u201387.","journal-title":"Lancet"},{"issue":"3","key":"3871_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","volume":"4","author":"WC Reygaert","year":"2018","unstructured":"Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482\u2013501.","journal-title":"AIMS Microbiol"},{"key":"3871_CR33","doi-asserted-by":"publisher","first-page":"3348695","DOI":"10.1155\/2022\/3348695","volume":"2022","author":"S Tao","year":"2022","unstructured":"Tao S, Chen H, Li N, Wang T, Liang W. The spread of antibiotic resistance genes in vivo model. Can J Infect Dis Med Microbiol. 2022;2022:3348695.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"6","key":"3871_CR34","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1128\/AAC.01707-08","volume":"53","author":"A Carattoli","year":"2009","unstructured":"Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009;53(6):2227\u201338.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3871_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160\u2013201.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"3871_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nrmicro2200","volume":"7","author":"HF Chambers","year":"2009","unstructured":"Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629\u201341.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"3871_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1046\/j.1365-2958.1999.01521.x","volume":"33","author":"R Hakenbeck","year":"1999","unstructured":"Hakenbeck R, Grebe T, Z\u00e4hner D, Stock JB. Beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol. 1999;33(4):673\u20138.","journal-title":"Mol Microbiol"},{"issue":"6","key":"3871_CR38","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1365-2958.1993.tb01253.x","volume":"9","author":"M Finken","year":"1993","unstructured":"Finken M, Kirschner P, Meier A, Wrede A, B\u00f6ttger EC. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol. 1993;9(6):1239\u201346.","journal-title":"Mol Microbiol"},{"issue":"8","key":"3871_CR39","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1128\/AAC.00864-15","volume":"59","author":"B Sharma","year":"2015","unstructured":"Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother. 2015;59(8):4616\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3871_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/CMR.00117-14","volume":"28","author":"X-Z Li","year":"2015","unstructured":"Li X-Z, Pl\u00e9siat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337\u2013418.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"3871_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/CMR.00043-12","volume":"25","author":"L Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25(4):661\u201381.","journal-title":"Clin Microbiol Rev"},{"key":"3871_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","volume":"12","author":"N Salari","year":"2023","unstructured":"Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12:57.","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"3871_CR43","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361.","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"3871_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrmicro2182","volume":"7","author":"M Otto","year":"2009","unstructured":"Otto M. Staphylococcus epidermidis \u2013 the \u201caccidental\u201d pathogen. Nat Rev Microbiol. 2009;7(8):555\u201367.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"3871_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1128\/JB.01464-06","volume":"189","author":"RT Cirz","year":"2007","unstructured":"Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN, et al. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J Bacteriol. 2007;189(2):531\u20139.","journal-title":"J Bacteriol"},{"issue":"3","key":"3871_CR46","doi-asserted-by":"publisher","first-page":"e00100","DOI":"10.1128\/mBio.00100-11","volume":"2","author":"I Keren","year":"2011","unstructured":"Keren I, Minami S, Rubin E, Lewis K. Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. mBio. 2011;2(3):e00100-11.","journal-title":"mBio"},{"issue":"4","key":"3871_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/em.22267","volume":"60","author":"KH Maslowska","year":"2019","unstructured":"Maslowska KH, Makiela-Dzbenska K, Fijalkowska IJ. The SOS system: a complex and tightly regulated response to DNA damage. Environ Mol Mutagen. 2019;60(4):368\u201384.","journal-title":"Environ Mol Mutagen"},{"key":"3871_CR48","doi-asserted-by":"publisher","first-page":"118562","DOI":"10.1016\/j.lfs.2020.118562","volume":"262","author":"MY Memar","year":"2020","unstructured":"Memar MY, Yekani M, Celenza G, Poortahmasebi V, Naghili B, Bellio P, et al. The central role of the SOS DNA repair system in antibiotics resistance: a new target for a new infectious treatment strategy. Life Sci. 2020;262:118562.","journal-title":"Life Sci"},{"key":"3871_CR49","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3389\/fmicb.2020.01785","volume":"11","author":"Z Podlesek","year":"2020","unstructured":"Podlesek Z, \u017dgur BD. The DNA damage inducible SOS response is a key player in the generation of bacterial persister cells and population wide tolerance. Front Microbiol. 2020;11:1785.","journal-title":"Front Microbiol"},{"issue":"12","key":"3871_CR50","doi-asserted-by":"publisher","first-page":"e0144763","DOI":"10.1371\/journal.pone.0144763","volume":"10","author":"BM Walter","year":"2015","unstructured":"Walter BM, Cartman ST, Minton NP, Butala M, Rupnik M. The SOS response master regulator LexA is associated with sporulation, motility and biofilm formation in Clostridium difficile. PLoS ONE. 2015;10(12):e0144763.","journal-title":"PLoS ONE"},{"issue":"1","key":"3871_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3871_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/microorganisms7060180","volume":"7","author":"SA Kraemer","year":"2019","unstructured":"Kraemer SA, Ramachandran A, Perron GG. Antibiotic pollution in the environment: from microbial ecology to public policy. Microorganisms. 2019;7(6):180.","journal-title":"Microorganisms"},{"issue":"Suppl 2","key":"3871_CR53","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1086\/519256","volume":"45","author":"SK Olofsson","year":"2007","unstructured":"Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis. 2007;45(Suppl 2):S129\u201336.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3871_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/MMBR.00016-10","volume":"74","author":"J Davies","year":"2010","unstructured":"Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417\u201333.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"3871_CR55","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrd3975","volume":"12","author":"K Lewis","year":"2013","unstructured":"Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov. 2013;12(5):371\u201387.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3871_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2202","volume":"6","author":"LL Silver","year":"2007","unstructured":"Silver LL. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov. 2007;6(1):41\u201355.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"3871_CR57","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/microorganisms9102041","volume":"9","author":"N Vaou","year":"2021","unstructured":"Vaou N, Stavropoulou E, Voidarou C, Tsigalou C, Bezirtzoglou E. Towards advances in medicinal plant antimicrobial activity: a review study on challenges and future perspectives. Microorganisms. 2021;9(10):2041.","journal-title":"Microorganisms"},{"issue":"5","key":"3871_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","volume":"18","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher U, Outterson K, Engel A, Karl\u00e9n A. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18(5):275\u201385.","journal-title":"Nat Rev Microbiol"},{"key":"3871_CR59","unstructured":"World Health Organization. 2023 antibacterial agents in clinical and preclinical development: an overview and analysis [Internet]. Geneva: WHO; 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240094000. Accessed 22 Sept 2024"},{"issue":"4","key":"3871_CR60","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1473-3099(15)00500-9","volume":"16","author":"JH Rex","year":"2016","unstructured":"Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16(4):500\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"3871_CR61","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/ph16111615","volume":"16","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals. 2023;16(11):1615.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"3871_CR62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41579-020-0379-y","volume":"18","author":"DA van Bergeijk","year":"2020","unstructured":"van Bergeijk DA, Terlouw BR, Medema MH, van Wezel GP. Ecology and genomics of actinobacteria: new concepts for natural product discovery. Nat Rev Microbiol. 2020;18(10):546\u201358.","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"3871_CR63","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/antibiotics13060476","volume":"13","author":"NA Zigangirova","year":"2024","unstructured":"Zigangirova NA, Lubenec NL, Beloborodov VB, Sheremet AB, Nelyubina SA, Bondareva NE, et al. A new \u201cnon-traditional\u201d antibacterial drug fluorothiazinone\u2014clinical research in patients with complicated urinary tract infections. Antibiotics. 2024;13(6):476.","journal-title":"Antibiotics"},{"issue":"11","key":"3871_CR64","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1128\/JB.00204-08","volume":"190","author":"Y Ohnishi","year":"2008","unstructured":"Ohnishi Y, Ishikawa J, Hara H, Suzuki H, Ikenoya M, Ikeda H, et al. Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350. J Bacteriol. 2008;190(11):4050\u201360.","journal-title":"J Bacteriol"},{"issue":"W1","key":"3871_CR65","doi-asserted-by":"publisher","first-page":"W81","DOI":"10.1093\/nar\/gkz310","volume":"47","author":"K Blin","year":"2019","unstructured":"Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee SY, et al. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic Acids Res. 2019;47(W1):W81-7.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3871_CR66","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.bbrc.2007.03.180","volume":"357","author":"S Hiard","year":"2007","unstructured":"Hiard S, Mar\u00e9e R, Colson S, Hoskisson PA, Titgemeyer F, van Wezel GP, et al. PREDetector: a new tool to identify regulatory elements in bacterial genomes. Biochem Biophys Res Commun. 2007;357(4):861\u20134.","journal-title":"Biochem Biophys Res Commun"},{"issue":"W1","key":"3871_CR67","doi-asserted-by":"publisher","first-page":"W49","DOI":"10.1093\/nar\/gkx320","volume":"45","author":"MA Skinnider","year":"2017","unstructured":"Skinnider MA, Merwin NJ, Johnston CW, Magarvey NA. PRISM 3: expanded prediction of natural product chemical structures from microbial genomes. Nucleic Acids Res. 2017;45(W1):W49-54.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"3871_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tibtech.2012.05.007","volume":"30","author":"VHT Pham","year":"2012","unstructured":"Pham VHT, Kim J. Cultivation of unculturable soil bacteria. Trends Biotechnol. 2012;30(9):475\u201384.","journal-title":"Trends Biotechnol"},{"issue":"7535","key":"3871_CR69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455\u20139.","journal-title":"Nature"},{"issue":"21","key":"3871_CR70","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1021\/acs.jmedchem.0c00173","volume":"63","author":"VB Gunjal","year":"2020","unstructured":"Gunjal VB, Thakare R, Chopra S, Reddy DS. Teixobactin: a paving stone toward a new class of antibiotics? J Med Chem. 2020;63(21):12171\u201395.","journal-title":"J Med Chem"},{"issue":"9","key":"3871_CR71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nchembio.2007.24","volume":"3","author":"AE Clatworthy","year":"2007","unstructured":"Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3(9):541\u20138.","journal-title":"Nat Chem Biol"},{"key":"3871_CR72","doi-asserted-by":"publisher","first-page":"106551","DOI":"10.1016\/j.bioorg.2023.106551","volume":"136","author":"A Vashistha","year":"2023","unstructured":"Vashistha A, Sharma N, Nanaji Y, Kumar D, Singh G, Barnwal RP, et al. Quorum sensing inhibitors as therapeutics: bacterial biofilm inhibition. Bioorg Chem. 2023;136:106551.","journal-title":"Bioorg Chem"},{"key":"3871_CR73","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3389\/fmicb.2016.01454","volume":"7","author":"R Garc\u00eda-Contreras","year":"2016","unstructured":"Garc\u00eda-Contreras R. Is quorum sensing interference a viable alternative to treat Pseudomonas aeruginosa infections? Front Microbiol. 2016;7:1454.","journal-title":"Front Microbiol"},{"key":"3871_CR74","doi-asserted-by":"publisher","first-page":"952633","DOI":"10.3389\/fmicb.2022.952633","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Cai Y, Liu Y, An H, Deng K, Ashraf MA, et al. Breaking down the cell wall: still an attractive antibacterial strategy. Front Microbiol. 2022;13:952633.","journal-title":"Front Microbiol"},{"issue":"10","key":"3871_CR75","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/fmb.12.97","volume":"7","author":"M Schmelcher","year":"2012","unstructured":"Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012;7(10):1147\u201371.","journal-title":"Future Microbiol"},{"issue":"3","key":"3871_CR76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/CMR.00056-05","volume":"19","author":"H Jenssen","year":"2006","unstructured":"Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19(3):491\u2013511.","journal-title":"Clin Microbiol Rev"},{"key":"3871_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12929-023-00919-1","volume":"30","author":"H Liu","year":"2023","unstructured":"Liu H, Hu Z, Li M, Yang Y, Lu S, Rao X. Therapeutic potential of bacteriophage endolysins for infections caused by gram-positive bacteria. J Biomed Sci. 2023;30:29.","journal-title":"J Biomed Sci"},{"issue":"30","key":"3871_CR78","doi-asserted-by":"publisher","first-page":"9836","DOI":"10.1021\/ja801662y","volume":"130","author":"K Lienkamp","year":"2008","unstructured":"Lienkamp K, Madkour AE, Musante A, Nelson CF, N\u00fcsslein K, Tew GN. Antimicrobial polymers prepared by ROMP with unprecedented selectivity: a molecular construction kit approach. J Am Chem Soc. 2008;130(30):9836\u201343.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"3871_CR79","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2005.12.008","volume":"71","author":"O Lomovskaya","year":"2006","unstructured":"Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic\u2014a vision for applied use. Biochem Pharmacol. 2006;71(7):910\u20138.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3871_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1389557033405359","volume":"3","author":"CA Hutton","year":"2003","unstructured":"Hutton CA, Southwood TJ, Turner JJ. Inhibitors of lysine biosynthesis as antibacterial agents. Mini Rev Med Chem. 2003;3(2):115\u201327.","journal-title":"Mini Rev Med Chem"},{"issue":"20","key":"3871_CR81","doi-asserted-by":"publisher","first-page":"11561","DOI":"10.1073\/pnas.95.20.11561","volume":"95","author":"SM Zeman","year":"1998","unstructured":"Zeman SM, Phillips DR, Crothers DM. Characterization of covalent Adriamycin-DNA adducts. Proc Natl Acad Sci U S A. 1998;95(20):11561\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3871_CR82","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/AAC.39.2.279","volume":"39","author":"P Huovinen","year":"1995","unstructured":"Huovinen P, Sundstr\u00f6m L, Swedberg G, Sk\u00f6ld O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother. 1995;39(2):279\u201389. https:\/\/doi.org\/10.1128\/AAC.39.2.279.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3871_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/antibiotics12010047","volume":"12","author":"MS Shaikh","year":"2023","unstructured":"Shaikh MS, Kale MA, Muralidharan V, Venkatachalam T, Ali SS, Islam F, et al. The design, synthesis, and evaluation of diaminopimelic acid derivatives as potential dapF inhibitors preventing lysine biosynthesis for antibacterial activity. Antibiotics. 2023;12(1):47. https:\/\/doi.org\/10.3390\/antibiotics12010047.","journal-title":"Antibiotics"},{"issue":"36","key":"3871_CR84","doi-asserted-by":"publisher","first-page":"24453","DOI":"10.1074\/jbc.M109.023861","volume":"284","author":"KC Ravindra","year":"2009","unstructured":"Ravindra KC, Selvi BR, Arif M, Reddy BAA, Thanuja GR, Agrawal S, et al. Inhibition of lysine acetyltransferase KAT3B\/P300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J Biol Chem. 2009;284(36):24453\u201364. https:\/\/doi.org\/10.1074\/jbc.M109.023861.","journal-title":"J Biol Chem"},{"issue":"8","key":"3871_CR85","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1128\/AAC.00412-13","volume":"57","author":"S-J Yang","year":"2013","unstructured":"Yang S-J, Xiong YQ, Yeaman MR, Bayles KW, Abdelhady W, Bayer AS. Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57(8):3875\u201382. https:\/\/doi.org\/10.1128\/AAC.00412-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3871_CR86","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1128\/AAC.38.6.1211","volume":"38","author":"JM Prins","year":"1994","unstructured":"Prins JM, van Deventer SJ, Kuijper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother. 1994;38(6):1211\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3871_CR87","doi-asserted-by":"publisher","first-page":"262","DOI":"10.18683\/germs.2022.1328","volume":"12","author":"R Dehbanipour","year":"2022","unstructured":"Dehbanipour R, Ghalavand Z. Anti-virulence therapeutic strategies against bacterial infections: recent advances. Germs. 2022;12(2):262\u201375. https:\/\/doi.org\/10.18683\/germs.2022.1328.","journal-title":"Germs"},{"issue":"7","key":"3871_CR88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2017.23","volume":"16","author":"SW Dickey","year":"2017","unstructured":"Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017;16(7):457\u201371. https:\/\/doi.org\/10.1038\/nrd.2017.23.","journal-title":"Nat Rev Drug Discov"},{"issue":"5892","key":"3871_CR89","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.1160354","volume":"321","author":"DA Rasko","year":"2008","unstructured":"Rasko DA, Moreira CG, Li DR, Reading NC, Ritchie JM, Waldor MK, et al. Targeting QseC signaling and virulence for antibiotic development. Science. 2008;321(5892):1078\u201380. https:\/\/doi.org\/10.1126\/science.1160354.","journal-title":"Science"},{"issue":"3","key":"3871_CR90","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acsinfecdis.1c00296","volume":"8","author":"M Sakari","year":"2022","unstructured":"Sakari M, Laisi A, Pulliainen AT. Exotoxin-targeted drug modalities as antibiotic alternatives. ACS Infect Dis. 2022;8(3):433\u201356. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00296.","journal-title":"ACS Infect Dis"},{"issue":"9","key":"3871_CR91","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(20)30995-6","volume":"21","author":"B Fran\u00e7ois","year":"2021","unstructured":"Fran\u00e7ois B, Jafri HS, Chastre J, S\u00e1nchez-Garc\u00eda M, Eggimann P, Dequin P-F, et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis. 2021;21(9):1313\u201323. https:\/\/doi.org\/10.1016\/S1473-3099(20)30995-6.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"3871_CR92","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/microorganisms9102049","volume":"9","author":"JA Hotinger","year":"2021","unstructured":"Hotinger JA, Morris ST, May AE. The case against antibiotics and for anti-virulence therapeutics. Microorganisms. 2021;9(10):2049. https:\/\/doi.org\/10.3390\/microorganisms9102049.","journal-title":"Microorganisms"},{"key":"3871_CR93","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13054-022-04204-9","volume":"26","author":"J Chastre","year":"2022","unstructured":"Chastre J, Fran\u00e7ois B, Bourgeois M, Komnos A, Ferrer R, Rahav G, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022;26:355. https:\/\/doi.org\/10.1186\/s13054-022-04204-9.","journal-title":"Crit Care"},{"key":"3871_CR94","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrd3013","volume":"9","author":"D Rasko","year":"2010","unstructured":"Rasko D, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117\u201328. https:\/\/doi.org\/10.1038\/nrd3013.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3871_CR95","doi-asserted-by":"publisher","first-page":"e02165","DOI":"10.1128\/mBio.02165-14","volume":"5","author":"MM Curtis","year":"2014","unstructured":"Curtis MM, Russell R, Moreira CG, Adebesin AM, Wang C, Williams NS, et al. QseC inhibitors as an antivirulence approach for Gram-negative pathogens. mBio. 2014;5(6):e02165-14. https:\/\/doi.org\/10.1128\/mBio.02165-14.","journal-title":"mBio"},{"key":"3871_CR96","doi-asserted-by":"publisher","first-page":"117138","DOI":"10.1016\/j.carbpol.2020.117138","volume":"252","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Dong Z, Wang L, Song R, Mei N, Chen T, et al. Cellulose membrane modified with LED209 as an antibacterial and anti-adhesion material. Carbohydr Polym. 2021;252:117138. https:\/\/doi.org\/10.1016\/j.carbpol.2020.117138.","journal-title":"Carbohydr Polym"},{"issue":"4","key":"3871_CR97","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/polysaccharides5040051","volume":"5","author":"M Sahiner","year":"2024","unstructured":"Sahiner M, Demirci S, Sahiner N. Super porous carboxymethyl cellulose\u2013tannic acid (TA@CMC) cryogels with antioxidant, antibacterial, and \u03b1-glucosidase enzyme inhibition abilities. Polysaccharides. 2024;5(4):823\u201341. https:\/\/doi.org\/10.3390\/polysaccharides5040051.","journal-title":"Polysaccharides"},{"issue":"12","key":"3871_CR98","doi-asserted-by":"publisher","first-page":"e01362","DOI":"10.1128\/AAC.01362-17","volume":"61","author":"D Maura","year":"2017","unstructured":"Maura D, Rahme LG. Pharmacological inhibition of the Pseudomonas aeruginosa MvfR quorum-sensing system interferes with biofilm formation and potentiates antibiotic-mediated biofilm disruption. Antimicrob Agents Chemother. 2017;61(12):e01362-e1417. https:\/\/doi.org\/10.1128\/AAC.01362-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3871_CR99","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41589-019-0401-8","volume":"16","author":"OM El-Halfawy","year":"2020","unstructured":"El-Halfawy OM, Czarny TL, Flannagan RS, Day J, Bozelli JC, Kuiack RC, et al. Discovery of an antivirulence compound that reverses \u03b2-lactam resistance in MRSA. Nat Chem Biol. 2020;16(2):143\u20139. https:\/\/doi.org\/10.1038\/s41589-019-0401-8.","journal-title":"Nat Chem Biol"},{"key":"3871_CR100","doi-asserted-by":"publisher","first-page":"107068","DOI":"10.1016\/j.micpath.2024.107068","volume":"197","author":"R Zhang","year":"2024","unstructured":"Zhang R, Liu Y, Wang S, Kang J, Song Y, Yin D, et al. Anti-bacteria, anti-biofilm, and anti-virulence activity of the synthetic compound MTEBT-3 against carbapenem-resistant Klebsiella pneumoniae strains ST3984. Microb Pathog. 2024;197:107068. https:\/\/doi.org\/10.1016\/j.micpath.2024.107068.","journal-title":"Microb Pathog"},{"issue":"6285","key":"3871_CR101","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1126\/science.aad9382","volume":"352","author":"EG Pamer","year":"2016","unstructured":"Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535\u20138.","journal-title":"Science"},{"issue":"2","key":"3871_CR102","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","volume":"361","author":"T-S Migone","year":"2009","unstructured":"Migone T-S, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361(2):135\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"3871_CR103","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Obiltoxaximab: First global approval. Drugs. 2016;76(7):823\u201330.","journal-title":"Drugs"},{"issue":"7","key":"3871_CR104","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1128\/AAC.01661-08","volume":"53","author":"M Bitzan","year":"2009","unstructured":"Bitzan M, Poole R, Mehran M, Sicard E, Brockus C, Thuning-Roberson C, et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother. 2009;53(7):3081\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"3871_CR105","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00134-018-5229-2","volume":"44","author":"B Fran\u00e7ois","year":"2018","unstructured":"Fran\u00e7ois B, Mercier E, Gonzalez C, Asehnoune K, Nseir S, Fiancette M, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018;44(11):1787\u201396.","journal-title":"Intensive Care Med"},{"key":"3871_CR106","doi-asserted-by":"publisher","first-page":"128779","DOI":"10.1016\/j.bmcl.2022.128779","volume":"69","author":"A Kimishima","year":"2022","unstructured":"Kimishima A, Hagimoto D, Honsho M, Watanabe Y, Iwatsuki M, Tsutsumi H, et al. Insights into the structure\u2013activity relationship of a type III secretion system inhibitor, aurodox. Bioorg Med Chem Lett. 2022;69:128779.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"3871_CR107","doi-asserted-by":"publisher","first-page":"e1004321","DOI":"10.1371\/journal.ppat.1004321","volume":"10","author":"M Starkey","year":"2014","unstructured":"Starkey M, Lepine F, Maura D, Bandyopadhaya A, Lesic B, He J, et al. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog. 2014;10(8):e1004321.","journal-title":"PLoS Pathog"},{"issue":"1","key":"3871_CR108","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13073-016-0307-y","volume":"8","author":"J Lloyd-Price","year":"2016","unstructured":"Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016;8(1):51.","journal-title":"Genome Med"},{"issue":"4","key":"3871_CR109","first-page":"479","volume":"95","author":"R Matzaras","year":"2022","unstructured":"Matzaras R, Nikopoulou A, Protonotariou E, Christaki E. Gut microbiota modulation and prevention of dysbiosis as an alternative approach to antimicrobial resistance: a narrative review. Yale J Biol Med. 2022;95(4):479\u201394.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"3871_CR110","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3920\/BM2016.0140","volume":"8","author":"AC Ouwehand","year":"2017","unstructured":"Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017;8(2):143\u201351.","journal-title":"Benef Microbes"},{"issue":"4","key":"3871_CR111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ajg.2013.59","volume":"108","author":"Z Kassam","year":"2013","unstructured":"Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3871_CR112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/NT.0000000000000167","volume":"51","author":"CD Davis","year":"2016","unstructured":"Davis CD. The gut microbiome and its role in obesity. Nutr Today. 2016;51(4):167\u201374.","journal-title":"Nutr Today"},{"issue":"2","key":"3871_CR113","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/03009734.2014.902878","volume":"119","author":"AS Nilsson","year":"2014","unstructured":"Nilsson AS. Phage therapy\u2013constraints and possibilities. Ups J Med Sci. 2014;119(2):192\u20138.","journal-title":"Ups J Med Sci"},{"issue":"4","key":"3871_CR114","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tig.2016.01.005","volume":"32","author":"RU Sheth","year":"2016","unstructured":"Sheth RU, Cabral V, Chen SP, Wang HH. Manipulating bacterial communities by in situ microbiome engineering. Trends Genet. 2016;32(4):189\u2013200.","journal-title":"Trends Genet"},{"issue":"7","key":"3871_CR115","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.3879","volume":"35","author":"DT Riglar","year":"2017","unstructured":"Riglar DT, Giessen TW, Baym M, Kerns SJ, Niederhuber MJ, Bronson RT, et al. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat Biotechnol. 2017;35(7):653\u20138.","journal-title":"Nat Biotechnol"},{"issue":"7613","key":"3871_CR116","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature18634","volume":"535","author":"A Zipperer","year":"2016","unstructured":"Zipperer A, Konnerth MC, Laux C, Berscheid A, Janek D, Weidenmaier C, et al. Human commensals producing a novel antibiotic impair pathogen colonization. Nature. 2016;535(7613):511\u20136.","journal-title":"Nature"},{"key":"3871_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.03.001","author":"J Wu","year":"2024","unstructured":"Wu J, Li L, Zhang T, Lu J, Tai Z, Zhu Q, et al. The epidermal lipid-microbiome loop and immunity: important players in atopic dermatitis. J Adv Res. 2024. https:\/\/doi.org\/10.1016\/j.jare.2024.03.001.","journal-title":"J Adv Res"},{"issue":"3","key":"3871_CR118","doi-asserted-by":"publisher","first-page":"e00026","DOI":"10.1128\/MMBR.00026-19","volume":"84","author":"K Schilcher","year":"2020","unstructured":"Schilcher K, Horswill AR. Staphylococcal biofilm development: structure, regulation, and treatment strategies. Microbiol Mol Biol Rev. 2020;84(3):e00026-e119.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"2","key":"3871_CR119","doi-asserted-by":"publisher","first-page":"e00205","DOI":"10.1128\/CMR.00205-20","volume":"34","author":"S Heilbronner","year":"2021","unstructured":"Heilbronner S, Foster TJ. Staphylococcus lugdunensis: a skin commensal with invasive pathogenic potential. Clin Microbiol Rev. 2021;34(2):e00205-e220.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"3871_CR120","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1038\/s41467-019-10646-7","volume":"10","author":"K Bitschar","year":"2019","unstructured":"Bitschar K, Sauer B, Focken J, Dehmer H, Moos S, Konnerth M, et al. Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors. Nat Commun. 2019;10(1):2730.","journal-title":"Nat Commun"},{"issue":"5","key":"3871_CR121","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.coi.2013.08.004","volume":"25","author":"GL Law","year":"2013","unstructured":"Law GL, Tisoncik-Go J, Korth MJ, Katze MG. Drug repurposing: a better approach for infectious disease drug discovery? Curr Opin Immunol. 2013;25(5):588\u201392.","journal-title":"Curr Opin Immunol"},{"issue":"D1","key":"3871_CR122","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51(D1):D1373\u201380.","journal-title":"Nucleic Acids Res"},{"key":"3871_CR123","first-page":"83","volume":"13","author":"MM Masadeh","year":"2021","unstructured":"Masadeh MM, Alzoubi KH, Masadeh MM, Aburashed ZO. Metformin as a potential adjuvant antimicrobial agent against multidrug resistant bacteria. Clin Pharmacol Adv Appl. 2021;13:83\u201390.","journal-title":"Clin Pharmacol Adv Appl"},{"key":"3871_CR124","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3389\/fmicb.2017.02101","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Li T, Wang D, Yang Y, Sun W, Liu J, et al. Synergistic antifungal effect of fluconazole combined with licofelone against resistant Candida albicans. Front Microbiol. 2017;8:2101.","journal-title":"Front Microbiol"},{"issue":"2","key":"3871_CR125","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cmet.2015.01.008","volume":"21","author":"B Peng","year":"2015","unstructured":"Peng B, Su Y-B, Li H, Han Y, Guo C, Tian Y-M, et al. Exogenous alanine and\/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 2015;21(2):249\u201362.","journal-title":"Cell Metab"},{"issue":"5","key":"3871_CR126","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/pharmaceutics12050417","volume":"12","author":"YH Choi","year":"2020","unstructured":"Choi YH. Interpretation of drug interaction using systemic and local tissue exposure changes. Pharmaceutics. 2020;12(5):417.","journal-title":"Pharmaceutics"},{"issue":"5","key":"3871_CR127","first-page":"600","volume":"50","author":"PV Turner","year":"2011","unstructured":"Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600\u201313.","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"4","key":"3871_CR128","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","volume":"57","author":"E Kim","year":"2023","unstructured":"Kim E, Yang J, Park S, Shin K. Factors Affecting Success of New Drug Clinical Trials. Ther Innov Regul Sci. 2023;57(4):737\u201350. https:\/\/doi.org\/10.1007\/s43441-023-00509-1.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"3871_CR129","doi-asserted-by":"publisher","first-page":"ofaa001","DOI":"10.1093\/ofid\/ofaa001","volume":"7","author":"JJ Darrow","year":"2020","unstructured":"Darrow JJ, Kesselheim AS. Incentivizing antibiotic development: why isn\u2019t the Generating Antibiotic Incentives Now (GAIN) Act working? Open Forum Infect Dis. 2020;7(1):ofaa001.","journal-title":"Open Forum Infect Dis"},{"issue":"2\u20133","key":"3871_CR130","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"W Mehnert","year":"2001","unstructured":"Mehnert W, M\u00e4der K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2\u20133):165\u201396.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"3871_CR131","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ijpharm.2012.07.033","volume":"436","author":"SP Chakraborty","year":"2012","unstructured":"Chakraborty SP, Sahu SK, Pramanik P, Roy S. In vitro antimicrobial activity of nanoconjugated vancomycin against drug resistant Staphylococcus aureus. Int J Pharm. 2012;436(1\u20132):659\u201376.","journal-title":"Int J Pharm"},{"issue":"1","key":"3871_CR132","doi-asserted-by":"publisher","first-page":"e202401857","DOI":"10.1002\/cbdv.202401857","volume":"22","author":"M Sahiner","year":"2025","unstructured":"Sahiner M, Tian Z, Demirci S, Sunol A, Allen-Gipson DS, Sahiner N. Bio-MOFs based on natural phenolic, hematoxylin leverages biomedical applications: enzyme inhibition, antioxidant, and antibacterial properties. Chem Biodivers. 2025;22(1):e202401857.","journal-title":"Chem Biodivers"},{"issue":"6","key":"3871_CR133","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10895-021-02798-x","volume":"31","author":"SS Suner","year":"2021","unstructured":"Suner SS, Sahiner M, Ayyala RS, Bhethanabotla VR, Sahiner N. Versatile fluorescent carbon dots from citric acid and cysteine with antimicrobial, anti-biofilm, antioxidant, and AChE enzyme inhibition capabilities. J Fluoresc. 2021;31(6):1705\u201317.","journal-title":"J Fluoresc"},{"key":"3871_CR134","doi-asserted-by":"publisher","first-page":"119531","DOI":"10.1016\/j.ijpharm.2020.119531","volume":"586","author":"DM Pardhi","year":"2020","unstructured":"Pardhi DM, \u015een Karaman D, Timonen J, Wu W, Zhang Q, Satija S, et al. Anti-bacterial activity of inorganic nanomaterials and their antimicrobial peptide conjugates against resistant and non-resistant pathogens. Int J Pharm. 2020;586:119531.","journal-title":"Int J Pharm"},{"issue":"4","key":"3871_CR135","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00253-009-2159-5","volume":"85","author":"W-R Li","year":"2010","unstructured":"Li W-R, Xie X-B, Shi Q-S, Zeng H-Y, Ou-Yang Y-S, Chen Y-B. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85(4):1115\u201322.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"3871_CR136","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3390\/molecules26072047","volume":"26","author":"M Ferreira","year":"2021","unstructured":"Ferreira M, Ogren M, Dias JNR, Silva M, Gil S, Tavares L, et al. Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance. Molecules. 2021;26(7):2047.","journal-title":"Molecules"},{"issue":"4","key":"3871_CR137","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3390\/pharmaceutics15041147","volume":"15","author":"R Stancheva","year":"2023","unstructured":"Stancheva R, Paunova-Krasteva T, Topouzova-Hristova T, Stoitsova S, Petrov P, Haladjova E. Ciprofloxacin-loaded mixed polymeric micelles as antibiofilm agents. Pharmaceutics. 2023;15(4):1147.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3871_CR138","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/2231-4040.82950","volume":"2","author":"VR Patel","year":"2011","unstructured":"Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2(2):81\u20137.","journal-title":"J Adv Pharm Technol Res"},{"key":"3871_CR139","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fphar.2019.00225","volume":"10","author":"Q Yuan","year":"2019","unstructured":"Yuan Q, Wang Y, Song R, Hou X, Yu K, Zheng J, et al. Study on formulation, in vivo exposure, and passive targeting of intravenous itraconazole nanosuspensions. Front Pharmacol. 2019;10:225.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3871_CR140","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"3871_CR141","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ejpb.2015.08.007","volume":"96","author":"M Gimeno","year":"2015","unstructured":"Gimeno M, Pinczowski P, P\u00e9rez M, Giorello A, Mart\u00ednez M\u00c1, Santamar\u00eda J, et al. A controlled antibiotic release system to prevent orthopedic-implant associated infections: An in vitro study. Eur J Pharm Biopharm. 2015;96:264\u201371.","journal-title":"Eur J Pharm Biopharm"},{"issue":"43","key":"3871_CR142","doi-asserted-by":"publisher","first-page":"40823","DOI":"10.1021\/acsomega.3c05924","volume":"8","author":"M Klicova","year":"2023","unstructured":"Klicova M, Mullerova S, Rosendorf J, Klapstova A, Jirkovec R, Erben J, et al. Large-scale development of antibacterial scaffolds: Gentamicin sulfate-loaded biodegradable nanofibers for gastrointestinal applications. ACS Omega. 2023;8(43):40823\u201335.","journal-title":"ACS Omega"},{"issue":"8","key":"3871_CR143","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/pharmaceutics14081739","volume":"14","author":"SS Suner","year":"2022","unstructured":"Suner SS, Sahiner M, Ayyala RS, Sahiner N. Degradable and non-degradable chondroitin sulfate particles with the controlled antibiotic release for bacterial infections. Pharmaceutics. 2022;14(8):1739.","journal-title":"Pharmaceutics"},{"key":"3871_CR144","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.msec.2014.08.031","volume":"44","author":"SM Dizaj","year":"2014","unstructured":"Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. Antimicrobial activity of the metals and metal oxide nanoparticles. Mater Sci Eng C Mater Biol Appl. 2014;44:278\u201384.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"3","key":"3871_CR145","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ppul.21356","volume":"46","author":"MW Konstan","year":"2011","unstructured":"Konstan MW, Geller DE, Mini\u0107 P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol. 2011;46(3):230\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"3871_CR146","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","volume":"22","author":"RL Nation","year":"2009","unstructured":"Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535\u201343.","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"3871_CR147","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/antibiotics9110776","volume":"9","author":"JA Santos","year":"2020","unstructured":"Santos JA, Lamers MH. Novel antibiotics targeting bacterial replicative DNA polymerases. Antibiotics. 2020;9(11):776.","journal-title":"Antibiotics"},{"issue":"5","key":"3871_CR148","doi-asserted-by":"publisher","first-page":"18","DOI":"10.22159\/ajpcr.2018.v11i5.23999","volume":"11","author":"R Priyanka","year":"2018","unstructured":"Priyanka R, Bhattacharyya S. A review on promising antibiotic therapy by novel delivery systems. Asian J Pharm Clin Res. 2018;11(5):18\u201324.","journal-title":"Asian J Pharm Clin Res"},{"key":"3871_CR149","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3389\/fchem.2019.00872","volume":"7","author":"D-Y Wang","year":"2019","unstructured":"Wang D-Y, van der Mei HC, Ren Y, Busscher HJ, Shi L. Lipid-based antimicrobial delivery systems for the treatment of bacterial infections. Front Chem. 2019;7:872.","journal-title":"Front Chem"},{"issue":"1","key":"3871_CR150","first-page":"4687959","volume":"2023","author":"AK Mahor","year":"2023","unstructured":"Mahor AK, Singh PP, Gupta R, Bhardwaj P, Rathore P, Kishore A, et al. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. J Nanotechnol. 2023;2023(1):4687959.","journal-title":"J Nanotechnol"},{"issue":"12","key":"3871_CR151","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/molecules26123587","volume":"26","author":"CMB Pinilla","year":"2021","unstructured":"Pinilla CMB, Lopes NA, Brandelli A. Lipid-based nanostructures for the delivery of natural antimicrobials. Molecules. 2021;26(12):3587.","journal-title":"Molecules"},{"issue":"14","key":"3871_CR152","doi-asserted-by":"publisher","first-page":"e2303654","DOI":"10.1002\/adhm.202303654","volume":"13","author":"J Werner","year":"2024","unstructured":"Werner J, Umst\u00e4tter F, Hertlein T, M\u00fchlberg E, Beijer B, Wohlfart S, et al. Oral delivery of the vancomycin derivative FU002 by a surface-modified liposomal nanocarrier. Adv Healthc Mater. 2024;13(14):e2303654.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"3871_CR153","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/21691401.2019.1593858","volume":"47","author":"J Ghaderkhani","year":"2019","unstructured":"Ghaderkhani J, Yousefimashouf R, Arabestani M, Roshanaei G, Asl SS, Abbasalipourkabir R. Improved antibacterial function of rifampicin-loaded solid lipid nanoparticles on Brucella abortus. Artif Cells Nanomed Biotechnol. 2019;47(1):1181\u201393.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"8","key":"3871_CR154","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/pharmaceutics14081668","volume":"14","author":"SE Alavi","year":"2022","unstructured":"Alavi SE, BakhtKoohiMoftakhariEsfahaniAdelniaAbdollahiEbrahimiShahmabadi UMHSHH, et al. A PEGylated nanostructured lipid carrier for enhanced oral delivery of antibiotics. Pharmaceutics. 2022;14(8):1668.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3871_CR155","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2017.1307209","volume":"46","author":"P Pushparaj Selvadoss","year":"2018","unstructured":"Pushparaj Selvadoss P, Nellore J, Balaraman Ravindrran M, Sekar U, Tippabathani J. Enhancement of antimicrobial activity by liposomal oleic acid-loaded antibiotics for the treatment of multidrug-resistant Pseudomonas aeruginosa. Artif Cells Nanomed Biotechnol. 2018;46(2):268\u201373.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"2","key":"3871_CR156","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/life13020446","volume":"13","author":"ID Zlotnikov","year":"2023","unstructured":"Zlotnikov ID, Streltsov DA, Belogurova NG, Kudryashova EV. Chitosan or cyclodextrin grafted with oleic acid self-assemble into stabilized polymeric micelles with potential of drug carriers. Life. 2023;13(2):446.","journal-title":"Life"},{"issue":"4","key":"3871_CR157","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/pharmaceutics13040435","volume":"13","author":"MA T\u0103nase","year":"2021","unstructured":"T\u0103nase MA, Raducan A, Oancea P, Di\u0163u LM, Stan M, Petcu C, et al. Mixed Pluronic-Cremophor polymeric micelles as nanocarriers for poorly soluble antibiotics\u2014the influence on the antibacterial activity. Pharmaceutics. 2021;13(4):435.","journal-title":"Pharmaceutics"},{"key":"3871_CR158","doi-asserted-by":"publisher","first-page":"110230","DOI":"10.1016\/j.msec.2019.110230","volume":"106","author":"L-Y Guo","year":"2020","unstructured":"Guo L-Y, Yan S-Z, Tao X, Yang Q, Li Q, Wang T-S, et al. Evaluation of Hypocrellin A-loaded lipase sensitive polymer micelles for intervening methicillin-resistant Staphylococcus aureus antibiotic-resistant bacterial infection. Mater Sci Eng C Mater Biol Appl. 2020;106:110230.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"12","key":"3871_CR159","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1021\/acsapm.0c01031","volume":"2","author":"G Zu","year":"2020","unstructured":"Zu G, Steinm\u00fcller M, Keskin D, van der Mei HC, Mergel O, van Rijn P. Antimicrobial nanogels with nanoinjection capabilities for delivery of the hydrophobic antibacterial agent triclosan. ACS Appl Polym Mater. 2020;2(12):5779\u201389.","journal-title":"ACS Appl Polym Mater"},{"issue":"12","key":"3871_CR160","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.1166\/jnn.2010.3003","volume":"10","author":"KK Bansal","year":"2010","unstructured":"Bansal KK, Kakde D, Gupta U, Jain NK. Development and characterization of triazine based dendrimers for delivery of antitumor agent. J Nanosci Nanotechnol. 2010;10(12):8395\u2013404.","journal-title":"J Nanosci Nanotechnol"},{"issue":"11","key":"3871_CR161","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/molecules26113304","volume":"26","author":"N Filipczak","year":"2021","unstructured":"Filipczak N, Yalamarty SSK, Li X, Parveen F, Torchilin V. Developments in treatment methodologies using dendrimers for infectious diseases. Molecules. 2021;26(11):3304.","journal-title":"Molecules"},{"issue":"5","key":"3871_CR162","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1021\/acs.bioconjchem.0c00121","volume":"31","author":"X Liu","year":"2020","unstructured":"Liu X, Wang Z, Feng X, Bai E, Xiong Y, Zhu X, et al. Platensimycin-encapsulated poly(lactic-co-glycolic acid) and poly(amidoamine) dendrimers nanoparticles with enhanced anti-staphylococcal activity in vivo. Bioconjug Chem. 2020;31(5):1425\u201337.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"3871_CR163","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1021\/acs.molpharmaceut.9b00713","volume":"16","author":"R Maji","year":"2019","unstructured":"Maji R, Omolo CA, Agrawal N, Maduray K, Hassan D, Mokhtar C, et al. pH-responsive lipid-dendrimer hybrid nanoparticles: an approach to target and eliminate intracellular pathogens. Mol Pharm. 2019;16(11):4594\u2013609.","journal-title":"Mol Pharm"},{"key":"3871_CR164","doi-asserted-by":"publisher","first-page":"106585","DOI":"10.1016\/j.ejps.2023.106585","volume":"190","author":"S Maru","year":"2023","unstructured":"Maru S, Verma J, Wilen C-E, Rosenholm JM, Bansal KK. Attenuation of celecoxib cardiac toxicity using poly(\u03b4-decalactone) based nanoemulsion via oral route. Eur J Pharm Sci. 2023;190:106585.","journal-title":"Eur J Pharm Sci"},{"key":"3871_CR165","doi-asserted-by":"publisher","DOI":"10.1039\/D4NA00176A","author":"P Dubey","year":"2024","unstructured":"Dubey P, Kumar A, Vaiphei KK, Basrani S, Jadhav A, Wilen C-E, et al. A poly-\u03b4-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against Candida albicans. Nanoscale Adv. 2024. https:\/\/doi.org\/10.1039\/D4NA00176A.","journal-title":"Nanoscale Adv"},{"issue":"40","key":"3871_CR166","doi-asserted-by":"publisher","first-page":"26455","DOI":"10.1039\/D2RA03925G","volume":"12","author":"HH Tayeb","year":"2022","unstructured":"Tayeb HH, Moqaddam SA, Hasaballah NH, Felimban RI. Development of nanoemulsions for the delivery of hydrophobic and hydrophilic compounds against carbapenem-resistant Klebsiella pneumoniae. RSC Adv. 2022;12(40):26455\u201362.","journal-title":"RSC Adv"},{"issue":"6","key":"3871_CR167","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/antibiotics12061066","volume":"12","author":"H Le","year":"2023","unstructured":"Le H, D\u00e9 E, Le Cerf D, Karakasyan C. Using targeted nano-antibiotics to improve antibiotic efficacy against Staphylococcus aureus infections. Antibiotics. 2023;12(6):1066.","journal-title":"Antibiotics"},{"issue":"10","key":"3871_CR168","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/pharmaceutics15102386","volume":"15","author":"KM Alarjani","year":"2023","unstructured":"Alarjani KM, Yehia HM, Badr AN, Ali HS, Al-Masoud AH, Alhaqbani SM, et al. Anti-MRSA and biological activities of propolis concentrations loaded to chitosan nanoemulsion for pharmaceutics applications. Pharmaceutics. 2023;15(10):2386.","journal-title":"Pharmaceutics"},{"issue":"8","key":"3871_CR169","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3390\/pharmaceutics15082133","volume":"15","author":"N Haddaji","year":"2023","unstructured":"Haddaji N, Bahloul B, Bahia W, Bechambi O, Mahdhi A. Development of nanotechnology-based drug delivery systems for controlling clinical multidrug-resistant Staphylococcus aureus and Escherichia coli associated with aerobic vaginitis. Pharmaceutics. 2023;15(8):2133.","journal-title":"Pharmaceutics"},{"issue":"46","key":"3871_CR170","doi-asserted-by":"publisher","first-page":"e1804559","DOI":"10.1002\/adma.201804559","volume":"30","author":"W Wang","year":"2018","unstructured":"Wang W, Zhang J, Zhang Q, Wan S, Zhu X, Zhang Q, et al. Self-adapting wettability of ReS2 under a constant stimulus. Adv Mater. 2018;30(46):e1804559.","journal-title":"Adv Mater"},{"issue":"1","key":"3871_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2017.68","volume":"3","author":"NC Seeman","year":"2017","unstructured":"Seeman NC, Sleiman HF. DNA nanotechnology. Nat Rev Mater. 2017;3(1):1\u201323.","journal-title":"Nat Rev Mater"},{"issue":"1","key":"3871_CR172","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-019-0611-0","volume":"27","author":"S Afrasiabi","year":"2020","unstructured":"Afrasiabi S, Pourhajibagher M, Raoofian R, Tabarzad M, Bahador A. Therapeutic applications of nucleic acid aptamers in microbial infections. J Biomed Sci. 2020;27(1):6.","journal-title":"J Biomed Sci"},{"issue":"3","key":"3871_CR173","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181\u2013202.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3871_CR174","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-024-48149-9","volume":"15","author":"J Yan","year":"2024","unstructured":"Yan J, Bhadane R, Ran M, Ma X, Li Y, Zheng D, et al. Development of aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy. Nat Commun. 2024;15(1):3684.","journal-title":"Nat Commun"},{"issue":"30","key":"3871_CR175","doi-asserted-by":"publisher","first-page":"e2300374","DOI":"10.1002\/adma.202300374","volume":"35","author":"J Yan","year":"2023","unstructured":"Yan J, Ran M, Shen X, Zhang H. Therapeutic DNAzymes: from structure design to clinical applications. Adv Mater. 2023;35(30):e2300374.","journal-title":"Adv Mater"},{"issue":"47","key":"3871_CR176","doi-asserted-by":"publisher","first-page":"e2304194","DOI":"10.1002\/smll.202304194","volume":"19","author":"M Ran","year":"2023","unstructured":"Ran M, Sun R, Yan J, Pulliainen AT, Zhang Y, Zhang H. DNA nanoflower eye drops with antibiotic-resistant gene regulation ability for MRSA keratitis target treatment. Small. 2023;19(47):e2304194.","journal-title":"Small"},{"issue":"1","key":"3871_CR177","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13756-020-00795-6","volume":"9","author":"B Aslam","year":"2020","unstructured":"Aslam B, Rasool M, Idris A, Muzammil S, Alvi RF, Khurshid M, et al. CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance. Antimicrob Resist Infect Control. 2020;9(1):131.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"10","key":"3871_CR178","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11095-020-02917-6","volume":"37","author":"GC Carvalho","year":"2020","unstructured":"Carvalho GC, S\u00e1bio RM, De C\u00e1ssia RT, Monteiro AS, Pereira DV, Ribeiro SJL, et al. Highlights in mesoporous silica nanoparticles as a multifunctional controlled drug delivery nanoplatform for infectious diseases treatment. Pharm Res. 2020;37(10):191.","journal-title":"Pharm Res"},{"issue":"5","key":"3871_CR179","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.actbio.2009.01.010","volume":"5","author":"X Shi","year":"2009","unstructured":"Shi X, Wang Y, Ren L, Zhao N, Gong Y, Wang D-A. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair. Acta Biomater. 2009;5(5):1697\u2013707.","journal-title":"Acta Biomater"},{"issue":"1","key":"3871_CR180","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12951-023-02093-w","volume":"21","author":"B Li","year":"2023","unstructured":"Li B, Liao Y, Su X, Chen S, Wang X, Shen B, et al. Powering mesoporous silica nanoparticles into bioactive nanoplatforms for antibacterial therapies: strategies and challenges. J Nanobiotechnol. 2023;21(1):325.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"3871_CR181","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/nano14020228","volume":"14","author":"I Otri","year":"2024","unstructured":"Otri I, Medaglia S, Mart\u00ednez-M\u00e1\u00f1ez R, Aznar E, Sancen\u00f3n F. Exploring the synergy between nano-formulated linezolid and polymyxin B as a Gram-negative effective antibiotic delivery system based on mesoporous silica nanoparticles. Nanomaterials. 2024;14(2):228.","journal-title":"Nanomaterials"},{"issue":"19","key":"3871_CR182","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1039\/C5TB02526E","volume":"4","author":"D \u015een Karaman","year":"2016","unstructured":"\u015een Karaman D, Sarwar S, Desai D, Bj\u00f6rk EM, Od\u00e9n M, Chakrabarti P, Rosenholm JM, Chakraborti S. Shape engineering boosts antibacterial activity of chitosan coated mesoporous silica nanoparticle doped with silver: A mechanistic investigation. J Mater Chem B. 2016;4(19):3292\u2013304.","journal-title":"J Mater Chem B"},{"key":"3871_CR183","first-page":"112607","volume":"133","author":"D Sen Karaman","year":"2021","unstructured":"Sen Karaman D, Kietz C, Govardhanam P, Slita A, Manea A, Pamukcu A, Meinander A, Rosenholm J. Core@shell structured ceria@mesoporous silica nanoantibiotics restrain bacterial growth in vitro and in vivo. Mater Sci Eng C. 2021;133:112607.","journal-title":"Mater Sci Eng C"},{"issue":"5","key":"3871_CR184","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/08853282241274517","volume":"39","author":"M Chamani","year":"2024","unstructured":"Chamani M, Asgari S, Najmeddin A, Pourjavadi A, Amin M, Gholami M, Dorkoosh FA. Antibacterial activity of a silver-incorporated vancomycin-modified mesoporous silica against methicillin-resistant Staphylococcus aureus. J Biomater Appl. 2024;39(5):439\u201354.","journal-title":"J Biomater Appl"},{"issue":"3","key":"3871_CR185","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/biomedicines11030706","volume":"11","author":"M Sahiner","year":"2023","unstructured":"Sahiner M, Yilmaz AS, Demirci S, Sahiner N. Physically and chemically crosslinked, tannic acid embedded linear PEI-based hydrogels and cryogels with natural antibacterial and antioxidant properties. Biomedicines. 2023;11(3):706.","journal-title":"Biomedicines"},{"issue":"36","key":"3871_CR186","doi-asserted-by":"publisher","first-page":"17134","DOI":"10.1007\/s10853-020-05253-7","volume":"55","author":"Z Gounani","year":"2020","unstructured":"Gounani Z, Pourianejad S, Asadollahi MA, Meyer RL, Rosenholm JM, Arpanaei A. Polycaprolactone-gelatin nanofibers incorporated with dual antibiotic-loaded carboxyl-modified silica nanoparticles. J Mater Sci. 2020;55(36):17134\u201350.","journal-title":"J Mater Sci"},{"issue":"130","key":"3871_CR187","doi-asserted-by":"publisher","first-page":"107839","DOI":"10.1039\/C5RA22976F","volume":"5","author":"T Tamanna","year":"2015","unstructured":"Tamanna T, Bulitta JB, Landersdorfer CB, Cashin V, Yu A. Stability and controlled antibiotic release from thin films embedded with antibiotic loaded mesoporous silica nanoparticles. RSC Adv. 2015;5(130):107839\u201346.","journal-title":"RSC Adv"},{"issue":"1","key":"3871_CR188","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/s41598-024-69102-2","volume":"14","author":"S-Y Byun","year":"2024","unstructured":"Byun S-Y, Han AR, Kim K-M, Kwon J-S. Antibacterial properties of mesoporous silica coated with cerium oxide nanoparticles in dental resin composite. Sci Rep. 2024;14(1):18014.","journal-title":"Sci Rep"},{"issue":"9","key":"3871_CR189","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1007\/s12274-024-6834-8","volume":"17","author":"W Su","year":"2024","unstructured":"Su W, Wang F, Chen B, Li R, Liu J, Xu J, Fan J, Liu Y. Photo-controllable antifouling hydrogels embedded with AgNPs coated spiropyran functionalized mesoporous silica for long-term antibacterial activity. Nano Res. 2024;17(9):8337\u201349.","journal-title":"Nano Res"},{"issue":"50","key":"3871_CR190","doi-asserted-by":"publisher","first-page":"58212","DOI":"10.1021\/acsami.3c13733","volume":"15","author":"M Verma","year":"2023","unstructured":"Verma M, Nisha A, Bathla M, Acharya A. Resveratrol-encapsulated glutathione-modified robust mesoporous silica nanoparticles as an antibacterial and antibiofilm coating agent for medical devices. ACS Appl Mater Interfaces. 2023;15(50):58212\u201329.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3871_CR191","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12951-017-0308-z","volume":"15","author":"YN Slavin","year":"2017","unstructured":"Slavin YN, Asnis J, H\u00e4feli UO, Bach H. Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. J Nanobiotechnol. 2017;15(1):65.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3871_CR192","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s11671-020-03344-7","volume":"15","author":"Z Yu","year":"2020","unstructured":"Yu Z, Li Q, Wang J, Yu Y, Wang Y, Zhou Q, Li P. Reactive oxygen species-related nanoparticle toxicity in the biomedical field. Nanoscale Res Lett. 2020;15(1):115.","journal-title":"Nanoscale Res Lett"},{"key":"3871_CR193","doi-asserted-by":"publisher","first-page":"130728","DOI":"10.1016\/j.jhazmat.2023.130728","volume":"446","author":"O Metryka","year":"2023","unstructured":"Metryka O, Wasilkowski D, Adamczyk-Habrajska M, Mrozik A. Undesirable consequences of the metallic nanoparticles action on the properties and functioning of Escherichia coli, Bacillus cereus and Staphylococcus epidermidis membranes. J Hazard Mater. 2023;446:130728.","journal-title":"J Hazard Mater"},{"issue":"6","key":"3871_CR194","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.arabjc.2015.08.008","volume":"10","author":"B Das","year":"2017","unstructured":"Das B, Dash SK, Mandal D, Ghosh T, Chattopadhyay S, Tripathy S, Das S, Dey SK, Das D, Roy S. Green synthesized silver nanoparticles destroy multidrug resistant bacteria via reactive oxygen species mediated membrane damage. Arab J Chem. 2017;10(6):862\u201376.","journal-title":"Arab J Chem"},{"issue":"1","key":"3871_CR195","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/1471-2180-13-301","volume":"13","author":"R Mempin","year":"2013","unstructured":"Mempin R, Tran H, Chen C, Gong H, Kim Ho K, Lu S. Release of extracellular ATP by bacteria during growth. BMC Microbiol. 2013;13(1):301.","journal-title":"BMC Microbiol"},{"issue":"51","key":"3871_CR196","doi-asserted-by":"publisher","first-page":"28240","DOI":"10.1021\/jacs.3c11463","volume":"145","author":"A Scheeder","year":"2023","unstructured":"Scheeder A, Brockhoff M, Ward EN, Kaminski Schierle GS, Mela I, Kaminski CF. Molecular mechanisms of cationic fusogenic liposome interactions with bacterial envelopes. J Am Chem Soc. 2023;145(51):28240\u201350.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"3871_CR197","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12951-022-01321-z","volume":"20","author":"S Dai","year":"2022","unstructured":"Dai S, Ye R, Huang J, Wang B, Xie Z, Ou X, Yu N, Huang C, Hua Y, Zhou R, Tian B. Distinct lipid membrane interaction and uptake of differentially charged nanoplastics in bacteria. J Nanobiotechnol. 2022;20(1):191.","journal-title":"J Nanobiotechnol"},{"issue":"22","key":"3871_CR198","doi-asserted-by":"publisher","first-page":"10695","DOI":"10.3390\/app112210695","volume":"11","author":"H Le","year":"2021","unstructured":"Le H, Karakasyan C, Jouenne T, Le Cerf D, D\u00e9 E. Application of polymeric nanocarriers for enhancing the bioavailability of antibiotics at the target site and overcoming antimicrobial resistance. Appl Sci. 2021;11(22):10695.","journal-title":"Appl Sci"},{"key":"3871_CR199","doi-asserted-by":"publisher","first-page":"114502","DOI":"10.1016\/j.addr.2022.114502","volume":"189","author":"A Nazli","year":"2022","unstructured":"Nazli A, He DL, Liao D, Khan MZI, Huang C, He Y. Strategies and progresses for enhancing targeted antibiotic delivery. Adv Drug Deliv Rev. 2022;189:114502.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3871_CR200","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jac\/dks379","volume":"68","author":"EA Azzopardi","year":"2013","unstructured":"Azzopardi EA, Ferguson EL, Thomas DW. The enhanced permeability retention effect: A new paradigm for drug targeting in infection. J Antimicrob Chemother. 2013;68(2):257\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3871_CR201","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1021\/acs.bioconjchem.1c00116","volume":"32","author":"A Alabresm","year":"2021","unstructured":"Alabresm A, Chandler SL, Benicewicz BC, Decho AW. Nanotargeting of resistant infections with a special emphasis on the biofilm landscape. Bioconjug Chem. 2021;32(8):1411\u201330.","journal-title":"Bioconjug Chem"},{"key":"3871_CR202","doi-asserted-by":"publisher","first-page":"134977","DOI":"10.1016\/j.ijbiomac.2024.134977","volume":"278","author":"GARR Naik","year":"2024","unstructured":"Naik GARR, Roy AA, Mutalik S, Dhas N. Unleashing the power of polymeric nanoparticles\u2014creative triumph against antibiotic resistance: a review. Int J Biol Macromol. 2024;278:134977.","journal-title":"Int J Biol Macromol"},{"key":"3871_CR203","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.2147\/IJN.S270204","volume":"15","author":"MM Farouk","year":"2020","unstructured":"Farouk MM, El-Molla A, Salib FA, Soliman YA, Shaalan M. The role of silver nanoparticles in a treatment approach for multidrug-resistant Salmonella species isolates. Int J Nanomedicine. 2020;15:6993\u20137011.","journal-title":"Int J Nanomedicine"},{"issue":"27","key":"3871_CR204","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1016\/j.biomaterials.2011.05.038","volume":"32","author":"US Toti","year":"2011","unstructured":"Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J, et al. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials. 2011;32(27):6606\u201313.","journal-title":"Biomaterials"},{"key":"3871_CR205","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2022.08.009","volume":"48","author":"P Manivasagan","year":"2023","unstructured":"Manivasagan P, Khan F, Rajan Dhatchayeny D, Park S, Joe A, Han H-W, et al. Antibody-conjugated and streptomycin-chitosan oligosaccharide-modified gold nanoshells for synergistic chemo-photothermal therapy of drug-resistant bacterial infection. J Adv Res. 2023;48:87\u2013104.","journal-title":"J Adv Res"},{"issue":"46","key":"3871_CR206","doi-asserted-by":"publisher","first-page":"e1804023","DOI":"10.1002\/adma.201804023","volume":"30","author":"C Wang","year":"2018","unstructured":"Wang C, Wang Y, Zhang L, Miron RJ, Liang J, Shi M, et al. Pretreated macrophage-membrane-coated gold nanocages for precise drug delivery for treatment of bacterial infections. Adv Mater. 2018;30(46):e1804023.","journal-title":"Adv Mater"},{"issue":"4","key":"3871_CR207","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1021\/acs.biomac.1c00082","volume":"22","author":"H Le","year":"2021","unstructured":"Le H, Arnoult C, D\u00e9 E, Schapman D, Galas L, Le Cerf D, et al. Antibody-conjugated nanocarriers for targeted antibiotic delivery: application in the treatment of bacterial biofilms. Biomacromol. 2021;22(4):1639\u201353.","journal-title":"Biomacromol"},{"key":"3871_CR208","doi-asserted-by":"publisher","unstructured":"Antibody-functionalized polymer nanoparticles for targeted antibiotic delivery in models of pathogenic bacteria infecting human macrophages. ACS Appl Mater Interfaces. 2023. https:\/\/doi.org\/10.1021\/acsami.3c07367.","DOI":"10.1021\/acsami.3c07367"},{"key":"3871_CR209","doi-asserted-by":"publisher","first-page":"814340","DOI":"10.3389\/fcimb.2022.814340","volume":"12","author":"P Ommen","year":"2022","unstructured":"Ommen P, Hansen L, Hansen BK, Vu-Quang H, Kjems J, Meyer RL. Aptamer-targeted drug delivery for Staphylococcus aureus biofilm. Front Cell Infect Microbiol. 2022;12:814340.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"3871_CR210","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11274-020-02845-y","volume":"36","author":"S Ucak","year":"2020","unstructured":"Ucak S, Sudagidan M, Borsa BA, Mansuroglu B, Ozalp VC. Inhibitory effects of aptamer targeted teicoplanin encapsulated PLGA nanoparticles for Staphylococcus aureus strains. World J Microbiol Biotechnol. 2020;36(5):69.","journal-title":"World J Microbiol Biotechnol"},{"issue":"11","key":"3871_CR211","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1021\/acs.bioconjchem.7b00368","volume":"28","author":"U Rajchakit","year":"2017","unstructured":"Rajchakit U, Sarojini V. Recent developments in antimicrobial-peptide-conjugated gold nanoparticles. Bioconjug Chem. 2017;28(11):2673\u201386.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"3871_CR212","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1021\/acsinfecdis.0c00264","volume":"6","author":"S Huo","year":"2020","unstructured":"Huo S, Chen C, Lyu Z, Zhang S, Wang Y, Nie B, et al. Overcoming planktonic and intracellular Staphylococcus aureus-associated infection with a cell-penetrating peptide-conjugated antimicrobial peptide. ACS Infect Dis. 2020;6(12):3147\u201362.","journal-title":"ACS Infect Dis"},{"issue":"11","key":"3871_CR213","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/catal12111376","volume":"12","author":"SS Suner","year":"2022","unstructured":"Suner SS, Sahiner M, Yilmaz AS, Ayyala RS, Sahiner N. Light-activated modified arginine carbon dots as antibacterial particles. Catalysts. 2022;12(11):1376.","journal-title":"Catalysts"},{"issue":"19","key":"3871_CR214","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.3390\/ma16196512","volume":"16","author":"SS Suner","year":"2023","unstructured":"Suner SS, Bhethanabotla VR, Ayyala RS, Sahiner N. Rapid pathogen purge by photosensitive arginine\u2013riboflavin carbon dots without toxicity. Materials. 2023;16(19):6512.","journal-title":"Materials"},{"issue":"6","key":"3871_CR215","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1039\/C9NR09687F","volume":"12","author":"W Zhang","year":"2020","unstructured":"Zhang W, Taheri-Ledari R, Hajizadeh Z, Zolfaghari E, Ahghari MR, Maleki A, et al. Enhanced activity of vancomycin by encapsulation in hybrid magnetic nanoparticles conjugated to a cell-penetrating peptide. Nanoscale. 2020;12(6):3855\u201370.","journal-title":"Nanoscale"},{"issue":"11","key":"3871_CR216","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/antibiotics10111338","volume":"10","author":"M Thambirajoo","year":"2021","unstructured":"Thambirajoo M, Maarof M, Lokanathan Y, Katas H, Ghazalli NF, Tabata Y, et al. Potential of nanoparticles integrated with antibacterial properties in preventing biofilm and antibiotic resistance. Antibiotics. 2021;10(11):1338.","journal-title":"Antibiotics"},{"issue":"7","key":"3871_CR217","doi-asserted-by":"publisher","first-page":"e2306135","DOI":"10.1002\/smll.202306135","volume":"20","author":"B Li","year":"2024","unstructured":"Li B, Mao J, Wu J, Mao K, Jia Y, Chen F, et al. Nano-bio interactions: biofilm-targeted antibacterial nanomaterials. Small. 2024;20(7):e2306135.","journal-title":"Small"},{"issue":"6","key":"3871_CR218","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/microorganisms11061614","volume":"11","author":"S Sharma","year":"2023","unstructured":"Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial biofilm: a review on formation, infection, antibiotic resistance, control measures, and innovative treatment. Microorganisms. 2023;11(6):1614.","journal-title":"Microorganisms"},{"issue":"42","key":"3871_CR219","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.1021\/bi00106a020","volume":"30","author":"M Rafalski","year":"1991","unstructured":"Rafalski M, Ortiz A, Rockwell A, Van Ginkel LC, Lear JD, DeGrado WF, et al. Membrane fusion activity of the influenza virus hemagglutinin: interaction of HA2 N-terminal peptides with phospholipid vesicles. Biochemistry. 1991;30(42):10211\u201320.","journal-title":"Biochemistry"},{"key":"3871_CR220","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jconrel.2022.12.002","volume":"353","author":"T Wang","year":"2023","unstructured":"Wang T, Cornel EJ, Li C, Du J. Drug delivery approaches for enhanced antibiofilm therapy. J Control Release. 2023;353:350\u201365.","journal-title":"J Control Release"},{"issue":"3","key":"3871_CR221","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1039\/C9NR08186K","volume":"12","author":"OK Kari","year":"2020","unstructured":"Kari OK, Ndika J, Parkkila P, Louna A, Lajunen T, Puustinen A, et al. In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow. Nanoscale. 2020;12(3):1728\u201341.","journal-title":"Nanoscale"},{"key":"3871_CR222","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1002\/SMMD.20230012","volume":"2","author":"R Mustafa","year":"2023","unstructured":"Mustafa R, Parkkila P, Rosenholm J, Zhang H, Viitala T. Monitoring silica core@shell nanoparticle-bacterial film interactions using the multi-parametric surface plasmon resonance technique. Smart Med. 2023;2:100012.","journal-title":"Smart Med"},{"issue":"3","key":"3871_CR223","doi-asserted-by":"publisher","first-page":"e01515","DOI":"10.1128\/spectrum.01515-22","volume":"12","author":"KN Shah","year":"2024","unstructured":"Shah KN, Shah PN, Agobe FO, Lovato K, Gao H, Ogun O, et al. Antimicrobial activity of a natural compound and analogs against multi-drug-resistant Gram-positive pathogens. Microbiol Spectr. 2024;12(3):e01515-e1522.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"3871_CR224","doi-asserted-by":"publisher","first-page":"e01804","DOI":"10.1128\/aem.01804-24","volume":"91","author":"Y Chen","year":"2025","unstructured":"Chen Y, Li W, Wang L, Wang B, Suo J. Novel inhibition of Staphylococcus aureus Sortase A by Plantamajoside: implications for controlling multidrug-resistant infections. Appl Environ Microbiol. 2025;91(1):e01804-e1824.","journal-title":"Appl Environ Microbiol"},{"key":"3871_CR225","doi-asserted-by":"publisher","first-page":"1361508","DOI":"10.3389\/fmicb.2024.1361508","volume":"15","author":"N Sun","year":"2024","unstructured":"Sun N, Zhi Z, Xiao T, Deng X, He T, Dong W, et al. The study of Honokiol as a natural product-based antimicrobial agent and its potential interaction with FtsZ protein. Front Microbiol. 2024;15:1361508.","journal-title":"Front Microbiol"},{"issue":"9","key":"3871_CR226","doi-asserted-by":"publisher","first-page":"e00611","DOI":"10.1128\/aac.00611-24","volume":"68","author":"L Liu","year":"2024","unstructured":"Liu L, Wang L, Liu X, Wang B, Guo X, Wang Y, et al. Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence. Antimicrob Agents Chemother. 2024;68(9):e00611-e624.","journal-title":"Antimicrob Agents Chemother"},{"key":"3871_CR227","doi-asserted-by":"publisher","first-page":"1500440","DOI":"10.3389\/fcimb.2024.1500440","volume":"14","author":"Z Shang","year":"2025","unstructured":"Shang Z, Sharma V, Pai L, Kumar T, Patil S. Optimizing the production and efficacy of antimicrobial bioactive compounds from Streptomyces kanamyceticus in combating multi-drug-resistant pathogens. Front Cell Infect Microbiol. 2025;14:1500440.","journal-title":"Front Cell Infect Microbiol"},{"key":"3871_CR228","doi-asserted-by":"publisher","first-page":"117138","DOI":"10.1016\/j.ejmech.2024.117138","volume":"283","author":"H Yang","year":"2025","unstructured":"Yang H, Li J, Wang B-L, Yang X-Y, Zhang Y. Discovery, synthesis, and antibacterial activity of novel myrtucommulone analogs as inhibitors of DNA gyrase and topoisomerase IV. Eur J Med Chem. 2025;283:117138.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3871_CR229","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ptr.8365","volume":"39","author":"S Ghosh","year":"2025","unstructured":"Ghosh S, Basu S, Anbarasu A, Ramaiah S. A comprehensive review of antimicrobial agents against clinically important bacterial pathogens: prospects for phytochemicals. Phytother Res. 2025;39(1):138\u201361.","journal-title":"Phytother Res"},{"issue":"48","key":"3871_CR230","doi-asserted-by":"publisher","first-page":"31466","DOI":"10.1039\/D2RA04385H","volume":"12","author":"T Al-Warhi","year":"2022","unstructured":"Al-Warhi T, Elimam DM, Elsayed ZM, Abdel-Aziz MM, Maklad RM, Al-Karmalawy AA, et al. Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens. RSC Adv. 2022;12(48):31466\u201377.","journal-title":"RSC Adv"},{"issue":"3","key":"3871_CR231","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jscs.2022.101447","volume":"26","author":"RR Bhandare","year":"2022","unstructured":"Bhandare RR, Munikrishnappa CS, Suresh Kumar GV, Konidala SK, Sigalapalli DK, Vaishnav Y, et al. Multistep synthesis and screening of heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents. J Saudi Chem Soc. 2022;26(3):47.","journal-title":"J Saudi Chem Soc"},{"key":"3871_CR232","doi-asserted-by":"publisher","first-page":"108104","DOI":"10.1016\/j.bioorg.2024.108104","volume":"154","author":"N Wang","year":"2025","unstructured":"Wang N, Yu H, Zhu Z, Wang H, Wei Y, Wang Q, et al. Novel methyldithiocarbazate derivatives as NDM-1 inhibitors to combat multidrug-resistant bacterial infection with \u03b2-lactams. Bioorg Chem. 2025;154:108104.","journal-title":"Bioorg Chem"},{"key":"3871_CR233","doi-asserted-by":"publisher","first-page":"117101","DOI":"10.1016\/j.ejmech.2024.117101","volume":"283","author":"X Lu","year":"2025","unstructured":"Lu X, Xu X, Ding Y, Gong X, Ming L, Dai X, et al. Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane. Eur J Med Chem. 2025;283:117101.","journal-title":"Eur J Med Chem"},{"issue":"24","key":"3871_CR234","doi-asserted-by":"publisher","first-page":"21781","DOI":"10.1021\/acs.jmedchem.4c01302","volume":"67","author":"FF Da Silva","year":"2024","unstructured":"Da Silva FF, Paz JD, Rambo RS, Gon\u00e7alves GA, Muniz MN, De Matos CA, et al. Unveiling the antimycobacterial potential of novel 4-alkoxyquinolines: insights into selectivity, mechanism of action, and in vivo exposure. J Med Chem. 2024;67(24):21781\u201394.","journal-title":"J Med Chem"},{"issue":"8","key":"3871_CR235","doi-asserted-by":"publisher","first-page":"e00164","DOI":"10.1128\/spectrum.00164-24","volume":"12","author":"C Giordano","year":"2024","unstructured":"Giordano C, Barnini S. Glycine restores the sensitivity to antibiotics in multidrug-resistant bacteria. Microbiol Spectr. 2024;12(8):e00164-e224.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"3871_CR236","doi-asserted-by":"publisher","first-page":"9863","DOI":"10.1038\/s41598-024-60627-0","volume":"14","author":"N Thadtapong","year":"2024","unstructured":"Thadtapong N, Chaturongakul S, Napaswad C, Dubbs P, Soodvilai S. Enhancing effect of natural adjuvant, Panduratin A, on antibacterial activity of colistin against multidrug-resistant Acinetobacter baumannii. Sci Rep. 2024;14(1):9863.","journal-title":"Sci Rep"},{"issue":"6","key":"3871_CR237","doi-asserted-by":"publisher","first-page":"e03227","DOI":"10.1128\/spectrum.03227-23","volume":"12","author":"S Tsutamoto","year":"2024","unstructured":"Tsutamoto S, Iwasaki Y, Shinohara A, Imamiya R, Samukawa K, Kawada-Matsuo M, et al. Triterpenoid saponin from Panax ginseng increases the sensitivity of methicillin-resistant Staphylococcus aureus to \u03b2-lactam and aminoglycoside antibiotics. Microbiol Spectr. 2024;12(6):e03227-e3323.","journal-title":"Microbiol Spectr"},{"key":"3871_CR238","doi-asserted-by":"publisher","first-page":"112755","DOI":"10.1016\/j.jinorgbio.2024.112755","volume":"262","author":"H-Y Huang","year":"2025","unstructured":"Huang H-Y, Xue R-Y, Xiao S-X, Huang L-T, Liao X-W, Wang J-T, et al. AIE-based ruthenium complexes as photosensitizers for specifically photo-inactivate Gram-positive bacteria. J Inorg Biochem. 2025;262:112755.","journal-title":"J Inorg Biochem"},{"issue":"15","key":"3871_CR239","doi-asserted-by":"publisher","first-page":"2400049","DOI":"10.1002\/adhm.202400049","volume":"13","author":"G Zhao","year":"2024","unstructured":"Zhao G, Lu G, Fan H, Wei L, Yu Q, Li M, et al. Herbal products-powered thermosensitive hydrogel with phototherapy and microenvironment reconstruction for accelerating multidrug-resistant bacteria-infected wound healing. Adv Healthc Mater. 2024;13(15):2400049.","journal-title":"Adv Healthc Mater"},{"key":"3871_CR240","doi-asserted-by":"publisher","first-page":"114288","DOI":"10.1016\/j.colsurfb.2024.114288","volume":"245","author":"S Hou","year":"2025","unstructured":"Hou S, Hong Y, Shang J, Wang Y, Shi X, Liu X, et al. Construction of BSA-ZnO&quercetin based multifunctional bionic self-assembly system and their antibacterial mechanism study. Colloids Surf B Biointerfaces. 2025;245:114288.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"3871_CR241","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1038\/s41467-024-52797-2","volume":"15","author":"CJ Barden","year":"2024","unstructured":"Barden CJ, Wu F, Fernandez-Murray JP, Lu E, Sun S, Taylor MM, Rushton AL, Williams J, Tavasoli M, Meek A, Reddy AS, Doyle LM, Sagamanova I, Sivamuthuraman K, Boudreau RTM, Byers DM, Weaver DF, McMaster CR. Computer-aided drug design to generate a unique antibiotic family. Nat Commun. 2024;15(1):8317.","journal-title":"Nat Commun"},{"key":"3871_CR242","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.compbiomed.2024.107927","volume":"169","author":"SO Oselusi","year":"2024","unstructured":"Oselusi SO, Dube P, Odugbemi AI, Akinyede KA, Ilori TL, Egieyeh E, Sibuyi NR, Meyer M, Madiehe AM, Wyckoff GJ, Egieyeh SA. The role and potential of computer-aided drug discovery strategies in the discovery of novel antimicrobials. Comput Biol Med. 2024;169:107927.","journal-title":"Comput Biol Med"},{"issue":"1","key":"3871_CR243","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43088-024-00473-1","volume":"13","author":"PJ Ameji","year":"2024","unstructured":"Ameji PJ, Uzairu A, Shallangwa GA, Uba S. Computer aided design of novel antibiotic drug candidate against multidrug resistant strains of Salmonella Typhi from pyridine-substituted coumarins. Beni-Suef Univ J Basic Appl Sci. 2024;13(1):15.","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"3871_CR244","doi-asserted-by":"publisher","first-page":"107496","DOI":"10.1016\/j.compbiomed.2023.107496","volume":"166","author":"A Tar\u00edn-Pell\u00f3","year":"2023","unstructured":"Tar\u00edn-Pell\u00f3 A, Suay-Garc\u00eda B, For\u00e9s-Martos J, Falc\u00f3 A, P\u00e9rez-Gracia M-T. Computer-aided drug repurposing to tackle antibiotic resistance based on topological data analysis. Comput Biol Med. 2023;166:107496.","journal-title":"Comput Biol Med"},{"key":"3871_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.864412","volume":"13","author":"M Juki\u010d","year":"2022","unstructured":"Juki\u010d M, Bren U. Machine learning in antibacterial drug design. Front Pharmacol. 2022;13: 864412.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3871_CR246","first-page":"7","volume":"11","author":"G-Y Liu","year":"2024","unstructured":"Liu G-Y, Yu D, Fan M-M, Zhang X, Jin Z-Y, Tang C, Liu X-F. Antimicrobial resistance crisis: Could artificial intelligence be the solution? Mil Med Res. 2024;11(1):7.","journal-title":"Mil Med Res"},{"issue":"1","key":"3871_CR247","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan AA. Lost in translation: The valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1):18.","journal-title":"Transl Med Commun"},{"issue":"6","key":"3871_CR248","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/ijp.ijp_860_22","volume":"54","author":"V Mahalmani","year":"2022","unstructured":"Mahalmani V, Sinha S, Prakash A, Medhi B. Translational research: Bridging the gap between preclinical and clinical research. Indian J Pharmacol. 2022;54(6):393\u20136.","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"3871_CR249","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/AAC.01454-17","volume":"62","author":"A Ito","year":"2018","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2018;62(1):e01454-e1517.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3871_CR250","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: A phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"3871_CR251","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"3871_CR252","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","volume":"66","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Mushtaq S, Warner M, Zhang J-C, Maharjan S, Doumith M, Woodford N. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"3871_CR253","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial. Infect Dis Ther. 2018. https:\/\/doi.org\/10.1007\/s40121-018-0214-1.","journal-title":"Infect Dis Ther"},{"key":"3871_CR254","doi-asserted-by":"crossref","unstructured":"Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):VMBF-0016\u20132015.","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"issue":"7","key":"3871_CR255","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2217\/fmb.15.39","volume":"10","author":"F Van Bambeke","year":"2015","unstructured":"Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: Evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10(7):1111\u201323.","journal-title":"Future Microbiol"},{"issue":"5","key":"3871_CR256","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"W O\u2019Riordan","year":"2018","unstructured":"O\u2019Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, Lawrence L, Liang S, Cammarata S, PROCEED Study Group. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: A phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67(5):657\u201366.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3871_CR257","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/gels9090708","volume":"9","author":"M Sahiner","year":"2023","unstructured":"Sahiner M, Yilmaz AS, Ayyala RS, Sahiner N. Carboxymethyl chitosan microgels for sustained delivery of vancomycin and long-lasting antibacterial effects. Gels. 2023;9(9):708.","journal-title":"Gels"},{"issue":"8","key":"3871_CR258","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40265-022-01725-z","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A, Lamb YN, Shirley M. Delafloxacin: A review in community-acquired pneumonia. Drugs. 2022;82(8):913\u201323.","journal-title":"Drugs"},{"issue":"6","key":"3871_CR259","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford PA, Miller AA, O\u2019Donnell J, Mueller JP. Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332\u201345.","journal-title":"ACS Infect Dis"},{"issue":"12","key":"3871_CR260","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","volume":"31","author":"J Retsema","year":"1987","unstructured":"Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother. 1987;31(12):1939\u201347.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3871_CR261","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/lam.13664","volume":"75","author":"DA Collins","year":"2022","unstructured":"Collins DA, Riley TV. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Lett Appl Microbiol. 2022;75(3):526\u201336.","journal-title":"Lett Appl Microbiol"},{"issue":"10","key":"3871_CR262","doi-asserted-by":"publisher","first-page":"e00250","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"F Wittke","year":"2020","unstructured":"Wittke F, Vincent C, Chen J, Heller B, Kabler H, Overcash JS, et al. Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin\/linezolid. Antimicrob Agents Chemother. 2020;64(10):e00250-e320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3871_CR263","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","volume":"16","author":"I Martin-Loeches","year":"2018","unstructured":"Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018;16(4):259\u201368.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3871_CR264","doi-asserted-by":"publisher","first-page":"212527","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.","journal-title":"Drugs Context"},{"issue":"Suppl 1","key":"3871_CR265","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1475-6773.13980","volume":"57","author":"AM Kilbourne","year":"2022","unstructured":"Kilbourne AM, Garrido MM, Brown AF. Translating research into policy and action. Health Serv Res. 2022;57(Suppl 1):5\u20138.","journal-title":"Health Serv Res"},{"issue":"13","key":"3871_CR266","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/healthcare11131946","volume":"11","author":"MA Salam","year":"2023","unstructured":"Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial resistance: a growing serious threat for global public health. Healthcare. 2023;11(13):1946.","journal-title":"Healthcare"},{"key":"3871_CR267","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20\u201333.","journal-title":"J Health Econ"},{"issue":"7","key":"3871_CR268","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","volume":"14","author":"MJ Waring","year":"2015","unstructured":"Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"3871_CR269","unstructured":"Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: The need for a One Health \u2013 One Europe \u2013 One World Framework [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2016. (Health Policy Series, No. 45.) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK447337\/. Accessed 09.06.2025"},{"issue":"6","key":"3871_CR270","doi-asserted-by":"publisher","first-page":"e1002043","DOI":"10.1371\/journal.pmed.1002043","volume":"13","author":"K Outterson","year":"2016","unstructured":"Outterson K, Gopinathan U, Clift C, So AD, Morel CM, R\u00f8ttingen J-A. Delinking investment in antibiotic research and development from sales revenues: the challenges of transforming a promising idea into reality. PLoS Med. 2016;13(6):e1002043.","journal-title":"PLoS Med"},{"issue":"2","key":"3871_CR271","first-page":"CD003543","volume":"2","author":"P Davey","year":"2017","unstructured":"Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2(2):CD003543.","journal-title":"Cochrane Database Syst Rev."},{"issue":"7","key":"3871_CR272","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","volume":"16","author":"EC Schuts","year":"2016","unstructured":"Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWT, Overdiek HWP, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):847\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"3871_CR273","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/S2542-5196(17)30141-9","volume":"1","author":"KL Tang","year":"2017","unstructured":"Tang KL, Caffrey NP, N\u00f3brega DB, Cork SC, Ronksley PE, Barkema HW, et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis. Lancet Planet Health. 2017;1(8):e316\u201327.","journal-title":"Lancet Planet Health"},{"issue":"18","key":"3871_CR274","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1073\/pnas.1503141112","volume":"112","author":"TP Van Boeckel","year":"2015","unstructured":"Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112(18):5649\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3871_CR275","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/03009734.2016.1195900","volume":"121","author":"D Jasovsk\u00fd","year":"2016","unstructured":"Jasovsk\u00fd D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance\u2014a threat to the world\u2019s sustainable development. Ups J Med Sci. 2016;121(3):159\u201364.","journal-title":"Ups J Med Sci"},{"issue":"7","key":"3871_CR276","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/trstmh\/trw048","volume":"110","author":"TP Robinson","year":"2016","unstructured":"Robinson TP, Bu DP, Carrique-Mas J, F\u00e8vre EM, Gilbert M, Grace D, et al. Antibiotic resistance is the quintessential One Health issue. Trans R Soc Trop Med Hyg. 2016;110(7):377\u201380.","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03871-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:02:17Z","timestamp":1751454137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03871-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":276,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3871"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03871-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"During the preparation of this manuscript, Gemini AI (2024), chatGPT-4o and ZeroGPT were used for the purpose of improving the language in chapters \u2018Antivirulence Approach\u2019 and \u2018Advancements in Antibiotic Formulation for Improved Delivery\u2019. The authors have reviewed and edited the output and take full responsibility for the content of this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of Artificial Intelligence"}}]}}